Data gathered: July 3
Alternative Data for Editas Medicine
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 12 | Sign up | Sign up | Sign up |
| Sentiment | 97 | Sign up | Sign up | Sign up |
| Webpage traffic | 22,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | 87 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 18 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 17,089 | Sign up | Sign up | Sign up |
| Twitter Mentions | 27 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 39 | Sign up | Sign up | Sign up |
| Business Outlook | 65 | Sign up | Sign up | Sign up |
| Linkedin Employees | 331 | Sign up | Sign up | Sign up |
About Editas Medicine
Editas Medicine is a clinical-stage biotechnology company which is developing therapies based on CRISPR–Cas9 gene editing technology. Editas is based in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
| Price | $4.65 |
| Target Price | Sign up |
| Volume | 362,090 |
| Market Cap | $375M |
| Year Range | $4.54 - $11.11 |
| Dividend Yield | 0% |
| Revenue per Employee | $314,115 |
| Industry | Biotechnology |
In the news
 |
Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now?June 29 - Yahoo |
 |
Zacks Research Comments on Editas Medicine, Inc.’s Q3 2025 Earnings (NASDAQ:EDIT)June 28 - ETF Daily News |
|
What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks with Highest Upside Potential?June 26 - Yahoo |
Editas Medicine Board Member Resigns, Effective June 2024June 26 - TipRanks |
|
|
Los Angeles Capital Management LLC Invests $1.10 Million in Editas Medicine, Inc. (NASDAQ:EDIT)June 24 - ETF Daily News |
|
Oppenheimer Reiterates Market Perform Rating for Editas Medicine (NASDAQ:EDIT)June 19 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '24 | 1.1M | 19M | -18M | -62M | -62M | -0.760 |
| Q4 '23 | 62M | 14M | 47M | -19M | -22M | -0.230 |
| Q3 '23 | 5.3M | 15M | -9.7M | -45M | -45M | -0.550 |
| Q2 '23 | 2.9M | 17M | -14M | -40M | -44M | -0.560 |
| Q1 '23 | 8.3M | 23M | -15M | -49M | -51M | -0.710 |
Insider Transactions View All
| Mei Baisong filed to sell 141,032 shares at $5.5. June 6 '24 |
| O'Neill Gilmore Neil filed to sell 315,279 shares at $5.5. June 6 '24 |
| Lucera Erick filed to sell 116,829 shares at $5.6. May 22 '24 |
| Hopfield Jessica filed to buy 67,700 shares at $5.6. May 14 '24 |
| O'Neill Gilmore Neil filed to sell 327,470 shares at $9.4. March 5 '24 |
Similar companies
Read more about Editas Medicine (EDIT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Editas Medicine?
The Market Cap of Editas Medicine is $375M.
How Many People Work at Editas Medicine?
As of our latest update, Editas Medicine employed approximately 226 people worldwide. However, it's important to note that Editas Medicine's workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.
What is Editas Medicine's revenue per employee?
$314,115. To calculate Editas Medicine's revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.
What is the current stock price of Editas Medicine?
Currently, the price of one share of Editas Medicine stock is $4.65.
How can I analyze the EDIT stock price chart for investment decisions?
The EDIT stock price chart above provides a comprehensive visual representation of Editas Medicine's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Editas Medicine shares. Our platform offers an up-to-date EDIT stock price chart, along with technical data analysis and alternative data insights.
Does EDIT offer dividends to its shareholders?
As of our latest update, Editas Medicine (EDIT) does not offer dividends to its shareholders. Investors interested in Editas Medicine should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Editas Medicine?
Some of the similar stocks of Editas Medicine are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.